jumonji domain containing 6, arginine demethylase and lysine hydroxylaseGenealiases: PSR · PTDSR · PTDSR1
Q-omics provides the consensus-scored JMJD6 profile across patient tissues and cancer cell-line models. JMJD6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, JMJD6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, JMJD6 protein abundance shows 20,616 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, KIRC, and LUAD as cancer lineages where JMJD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for JMJD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes JMJD6 survival associations across molecular data types. JMJD6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible JMJD6 RNA expression–survival associations across cancer types. High JMJD6 expression shows unfavorable associations in KIRP, MESO, ACC, LIHC, KIRC and UVM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for JMJD6 RNA expression.
This table summarizes JMJD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for JMJD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. JMJD6 shows higher tumor expression in KIRC, COAD, KIRP, LIHC, HNSC and CHOL. The KIRC box plot shows higher JMJD6 RNA expression in tumor versus normal tissue (log2 FC = +0.912, t-test p < 0.001).
This table shows molecular features associated with JMJD6 in patient tissues and cancer cell lines. In patient samples, JMJD6 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, JMJD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
